Abstract
One of the most serious complications of modern anesthesia is malignant hyperthermia, which is a pharmacogenetic
 disease phenotype manifested by skeletal muscle hypermetabolism and rhabdomyolysis during or after general anesthe-
 sia with the use of inhaled anesthetics and succinylcholine. In Russia, the problem of malignant hyperthermia remains
 unresolved. This is mainly due to the fact that the only specific drug dantrolene created for the effective treatment of
 malignant hyperthermia is still not legalized and thus formally prohibited to import, disseminate and apply on the
 domestic pharmaceutical market. This article deals with the regulatory framework of specific treatment of malignant
 hyperthermia in Russia, allowing the possibility to legally import to the territory of the Russian Federation dantrolene
 as an unregistered drug, if it is a question of rendering medical assistance on vital indications to a particular patient, or
 its unauthorized use for vital indications in a situation of extreme necessity. The article presents the recommendations
 of domestic experts on the treatment of malignant hyperthermia. In this case, as a possible alternative to dantrolene,
 magnesium preparations are considered, whose role in the treatment of the crisis of malignant hyperthermia continues
 to be specified.
 Thus, given the increasing use of inhalation anesthesia by Russian anesthetists, to ensure the safety of patients with
 regard to the development of malignant hyperthermia, it is possible only in the case of official registration in the do-
 mestic dantrolene market. Also, in the territory of Russia, a network of relevant consultative and diagnostic centers
 should be established. These measures will undoubtedly increase the effectiveness of treatment and prevention of severe
 consequences of this disease in our country.
Highlights
Одним из наиболее тяжёлых осложнений современной анестезии является злокачественная гипертермия, являющаяся фармакогенетическим заболеванием, фенотипически проявляющимся гиперметаболизмом скелетных мышц и рабдомиолизом во время или после проведения общей анестезии с применением ингаляционных анестетиков и сукцинилхолина
One of the most serious complications of modern anesthesia is malignant hyperthermia, which is a pharmacogenetic disease phenotype manifested by skeletal muscle hypermetabolism and rhabdomyolysis during or after general anesthesia with the use of inhaled anesthetics and succinylcholine
In Russia, the problem of malignant hyperthermia remains unresolved. This is mainly due to the fact that the only specific drug dantrolene created for the effective treatment of malignant hyperthermia is still not legalized and formally prohibited to import, disseminate and apply on the domestic pharmaceutical market
Summary
Одним из наиболее тяжёлых осложнений современной анестезии является злокачественная гипертермия, являющаяся фармакогенетическим заболеванием, фенотипически проявляющимся гиперметаболизмом скелетных мышц и рабдомиолизом во время или после проведения общей анестезии с применением ингаляционных анестетиков и сукцинилхолина. В России проблема злокачественной гипертермии в настоящее время остаётся нерешённой. Главным образом это объясняется тем, что на отечественном фармацевтическом рынке по-прежнему не легализован и, соответственно, официально запрещён к ввозу, распространению и применению единственный специфический препарат, созданный для эффективного лечения злокачественной гипертермии, – дантролен.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
